Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
By integrating orthogonal microtubule inhibition and high-linear-energy-transfer alpha irradiation on a single CD46 scaffold, potent, well-tolerated tumor control was achieved across diverse models. The dual-payload construct's compatibility with CD46 immuno-PET for real-time dosimetry further supports progression to early-phase clinical trials in prostate cancer and multiple myeloma.
Authors
- Shubhankar Naik (ORCID: https://orcid.org/0000-0002-9640-1188)
- Nancy Greenland (ORCID: https://orcid.org/0000-0002-1783-1711)
- Anju Wadhwa (ORCID: https://orcid.org/0009-0006-0826-8134)
- Jiang He (ORCID: https://orcid.org/0000-0001-7600-4604)
- Anil P. Bidkar (ORCID: https://orcid.org/0000-0003-1249-1081)
- Veronica Steri (ORCID: https://orcid.org/0000-0003-2499-6618)
- Scott Bidlingmaier (ORCID: https://orcid.org/0000-0003-4955-9713)
- Kondapa Naidu Bobba (ORCID: https://orcid.org/0000-0001-6304-2855)
- Megha Basak (ORCID: https://orcid.org/0000-0002-2422-184X)
- Athira Raveendran (ORCID: https://orcid.org/0000-0002-4853-4330)
- Juan A. Cámara (ORCID: https://orcid.org/0000-0001-7494-1127)
- Henry F. VanBrocklin (ORCID: https://orcid.org/0000-0003-2849-0841)
- R. Flavell
- Arun P. Wiita
- Bonell Patiño-Escobar
- Rahul Aggarwal
- Cheng Xue
- Youngho Seo
- David M. Wilson
- Jonathan Chou
- Bin Liu
- Ellis Mayne
Institutions
- University of California, San Francisco (US)
- Parker Institute for Cancer Immunotherapy (US)
- Chan Zuckerberg Initiative (United States) (US)
- University of Virginia Medical Center (US)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
- University of Virginia (US)
- University of California, Berkeley (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-01-22
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-4110
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00